Nephropathy caused by diabetes type 2. Diabetes mellitus With renal complications Diabetic nephropathy (N08.3*)
Conditions
Interventions
Intervention 1: intervention group:routine treatment+blueberry cap qID,2 months. Intervention 2: control group:routine treatment+placebo cap qID,2 months.
Treatment - Drugs
Placebo
intervention group:routine treatment+blueberry cap qID,2 months
control group:routine treatment+placebo cap qID,2 months
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: inclusion criteria: patients 20 to 75 years old receiving reducer blood glucose drug and dietary recommendations for at least 6 month with type II diabetes. That the urine microalbumin and the amount of protein in urine 24 hours higher than normal and receive a fixed dose of either or both ACEI or ARB at least 3 months. Exclusion criteria: certain underlying diseases such as autoimmune diseases or cancer, allergies to plants used in the clinical trial, pregnancy and breastfeeding, dialysis.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The 24-hour urine protein excretion. Timepoint: Before the intervention, one month after the intervention and after the end of the intervention. Method of measurement: 24-hour urine test.;Urine microalbumin excretion. Timepoint: Before the intervention, one month after the intervention and after the end of the intervention. Method of measurement: urine test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum BUN. Timepoint: The beginning and end of the intervention. Method of measurement: blood tests.;Serum Creatinine. Timepoint: The beginning and end of the intervention. Method of measurement: blood tests.;Fasting Blood Sugar. Timepoint: The beginning and end of the intervention. Method of measurement: blood tests.;BMI. Timepoint: The beginning and end of the intervention. Method of measurement: blood tests.;GFR. Timepoint: The beginning and end of the intervention. Method of measurement: blood tests.;HDL. Timepoint: The beginning and end of the intervention. Method of measurement: blood tests.;LDL. Timepoint: The beginning and end of the intervention. Method of measurement: blood tests.;Cholesterol. Timepoint: The beginning and end of the intervention. Method of measurement: blood tests.;TG. Timepoint: The beginning and end of the intervention. Method of measurement: blood tests. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactPouya Faridi
Shiraz University of Medical Sciences
Outcome results
None listed